MX2023004603A - Compuestos de furanopirimidina sustituida como inhibidores de pde1. - Google Patents

Compuestos de furanopirimidina sustituida como inhibidores de pde1.

Info

Publication number
MX2023004603A
MX2023004603A MX2023004603A MX2023004603A MX2023004603A MX 2023004603 A MX2023004603 A MX 2023004603A MX 2023004603 A MX2023004603 A MX 2023004603A MX 2023004603 A MX2023004603 A MX 2023004603A MX 2023004603 A MX2023004603 A MX 2023004603A
Authority
MX
Mexico
Prior art keywords
disorders
treating
sup
cognitive
methods
Prior art date
Application number
MX2023004603A
Other languages
English (en)
Inventor
Brian Dyck
Margaret Mccarrick
Demichael Chung
Brett Bookser
Iriny Botrous
Aaron Burns
Andrew Kleinke
Dange Vijay Kumar
Nicholas Raffaele
Joe Tran
Michael Weinhouse
Original Assignee
Dart Neuroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Llc filed Critical Dart Neuroscience Llc
Publication of MX2023004603A publication Critical patent/MX2023004603A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Entidades químicas de furanopirimidina sustituidas de Fórmula (I): (ver Fórmula), en donde Ra tiene cualquiera de los valores descritos en la presente y composiciones que comprenden estas entidades químicas; métodos para elaborarlas; y su uso en una amplia variedad de métodos, incluidos estudios cinéticos metabólicos y de reacción; técnicas de detección e imagen; terapias radiactivas; modulación y tratamiento de trastornos mediados por la actividad de PDE1 o señalización dopaminérgica; tratamiento de trastornos neurológicos, trastornos del CNS, demencia, enfermedades neurodegenerativas y pérdidas de función dependientes del trauma; tratamiento de accidentes cerebrovasculares, incluidos déficits cognitivos y motrices durante la rehabilitación de accidentes cerebrovasculares; facilitación de la neuroprotección y neurorecuperación; mejora de la eficiencia del entrenamiento cognitivo y motriz, incluidos protocolos de entrenamiento de expertos en animales; y tratamiento de trastornos periféricos, incluidos trastornos cardiovasculares, renales, hematológicos, gastroenterológicos, hepáticos, cancerosos, de fertilidad y metabólicos.
MX2023004603A 2017-11-27 2020-07-13 Compuestos de furanopirimidina sustituida como inhibidores de pde1. MX2023004603A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762591105P 2017-11-27 2017-11-27

Publications (1)

Publication Number Publication Date
MX2023004603A true MX2023004603A (es) 2023-05-08

Family

ID=64665119

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020005447A MX2020005447A (es) 2017-11-27 2018-11-26 Compuestos de furanopirimidina sustituida como inhibidores de pde1.
MX2023004603A MX2023004603A (es) 2017-11-27 2020-07-13 Compuestos de furanopirimidina sustituida como inhibidores de pde1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020005447A MX2020005447A (es) 2017-11-27 2018-11-26 Compuestos de furanopirimidina sustituida como inhibidores de pde1.

Country Status (11)

Country Link
US (2) US11434247B1 (es)
EP (1) EP3717488B1 (es)
JP (1) JP7254078B2 (es)
KR (1) KR20200108419A (es)
CN (1) CN111655695A (es)
AU (1) AU2018373258B2 (es)
CA (1) CA3120971A1 (es)
DK (1) DK3717488T3 (es)
ES (1) ES2902365T3 (es)
MX (2) MX2020005447A (es)
WO (1) WO2019104285A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981916B2 (en) 2016-12-28 2021-04-20 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors
TW202202495A (zh) 2020-03-26 2022-01-16 匈牙利商羅特格登公司 作為ｇａｍｍａ－胺基丁酸Ａ受體次單元ａｌｐｈａ ５受體調節劑之㖠啶及吡啶并〔３，４－ｃ〕嗒𠯤衍生物
US20240043400A1 (en) * 2020-12-03 2024-02-08 UCB Biopharma SRL Octahydroisoquinolinyl Derivatives
JP2024529020A (ja) * 2021-08-06 2024-08-01 レイゼビオ，インク． 細胞内ｋｒａｓ ｇ１２ｃタンパク質を標的とするための共有結合剤を含むコンジュゲート
WO2023115002A1 (en) * 2021-12-16 2023-06-22 Terran Biosciences Inc. Analogs of 4-bromo-2,5-dimethoxyphenethylamine

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982003626A1 (en) 1981-04-22 1982-10-28 Gauri Kailash Kumar New derivatives of pyrazolo(3,4-d)pyrimidine,preparation method thereof and remedy containing them
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
ZA914727B (en) 1990-06-21 1992-03-25 Schering Corp Polycyclic guanine derivatives
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
AU681875B2 (en) 1993-02-26 1997-09-11 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
WO1996028448A1 (en) 1995-03-10 1996-09-19 Sanofi Winthrop, Inc. 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
ZA969888B (en) 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE19838300A1 (de) 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100297814B1 (ko) 1998-12-29 2001-10-26 조민호 피라졸로피리미디논유도체와이의제조방법그리고이의용도
JP2004505054A (ja) 2000-08-01 2004-02-19 バイエル　アクチェンゲゼルシャフト 知覚を改善する医薬品としての選択的ｐｄｅ２インヒビター
EP1355669B1 (en) 2000-08-10 2011-09-28 Cold Spring Harbor Laboratory Augmented cognitive training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
JP2005508904A (ja) 2001-09-11 2005-04-07 スミスクライン ビーチャム コーポレーション 血管新生阻害剤としてのフロ−及びチエノピリミジン誘導体
WO2003053975A1 (fr) 2001-12-13 2003-07-03 Daiichi Suntory Pharma Co., Ltd. Derives de pyrazolopyrimidinone possedant une activite inhibitrice de pde7
US20040241706A1 (en) 2002-09-13 2004-12-02 Irm, Llc Highly specific modulators of GTPases for target validation
PT1539753E (pt) 2002-09-16 2009-12-10 Glaxo Group Ltd Compostos de pirazolo(3,4-b)piridina e sua utilização como inibidores da fosfodiesterase
ATE368666T1 (de) 2003-03-18 2007-08-15 Jordanian Pharmaceutical Mfg Pyrazolopyrimidinone und ihre verwendung als pde inhibitoren
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
DE102005061170A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
KR20090042227A (ko) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2008055959A1 (en) 2006-11-09 2008-05-15 Galapagos N.V. Novel compounds useful for the treatment of degenerative & inflammatory diseases
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
NZ580904A (en) 2007-05-11 2012-02-24 Pfizer Amino-heterocyclic compounds for inhibiting pde9
KR20100017422A (ko) 2007-05-15 2010-02-16 헬리콘 테라퓨틱스 인코퍼레이티드 작은 간섭 ＲＮＡ(ｓｉＲＮＡ)를 이용하여 기억 형성에 관여하는 유전자를 확인하는 방법
WO2009067166A2 (en) 2007-11-20 2009-05-28 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
AU2008331833A1 (en) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Organic compounds
CN104402893A (zh) 2007-12-06 2015-03-11 武田药品工业株式会社 有机化合物
KR20110092267A (ko) 2008-09-10 2011-08-17 칼립시스, 인코포레이티드 질환의 치료를 위한 히스타민 수용체의 아미노피리미딘 억제제
CA2740385A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
SG171777A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
WO2010065153A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
JP5879336B2 (ja) 2010-05-31 2016-03-08 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201219401A (en) 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
SG189837A1 (en) 2010-10-08 2013-06-28 Abbvie Inc FURO[3,2-d]PYRIMIDINE COMPOUNDS
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
EP2644590A1 (en) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts
KR102191816B1 (ko) 2012-06-18 2020-12-17 다트 뉴로사이언스 (케이만) 엘티디. 치환된 피리딘 아졸로피리미딘-5-(6h)-온 화합물
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR102148355B1 (ko) 2012-07-27 2020-08-26 사토 파머슈티컬 가부시키가이샤 디플루오로메틸렌 화합물
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
CA2908482A1 (en) 2013-03-01 2014-09-04 Fundacion Para La Investigacion Medica Aplicada Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
US10005764B2 (en) 2014-04-04 2018-06-26 H. Lundbeck A/S Halogenated quinazolin-THF-amines as PDE1 inhibitors
JP2017523204A (ja) 2014-08-04 2017-08-17 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ 認知向上のために用いる新規化合物
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
JP2017527606A (ja) 2014-09-18 2017-09-21 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 三環系誘導体
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
TW201639851A (zh) 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1
EP3269370B1 (en) 2016-02-23 2020-01-08 Taiho Pharmaceutical Co., Ltd. Novel condensed pyrimidine compound or salt thereof
TWI729109B (zh) * 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10981916B2 (en) 2016-12-28 2021-04-20 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
US20190177327A1 (en) 2017-10-13 2019-06-13 Dart Neuroscience, Llc Substituted methyl pyrazolopyrimidinone and methyl imidazopyrazinone compounds as pde1 inhibitors
US11434247B1 (en) 2017-11-27 2022-09-06 Dart Neuroscience Llc Substituted furanopyrimidine compounds as PDE1 inhibitors

Also Published As

Publication number Publication date
EP3717488A1 (en) 2020-10-07
AU2018373258B2 (en) 2023-03-02
MX2020005447A (es) 2020-12-03
AU2018373258A1 (en) 2020-07-16
JP7254078B2 (ja) 2023-04-07
KR20200108419A (ko) 2020-09-18
EP3717488B1 (en) 2021-09-29
CA3120971A1 (en) 2019-05-31
US12006325B2 (en) 2024-06-11
WO2019104285A1 (en) 2019-05-31
ES2902365T3 (es) 2022-03-28
CN111655695A (zh) 2020-09-11
DK3717488T3 (da) 2021-12-13
JP2021504380A (ja) 2021-02-15
US11434247B1 (en) 2022-09-06
US20230295178A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
MX2023004603A (es) Compuestos de furanopirimidina sustituida como inhibidores de pde1.
NZ725161A (en) Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors
MX370188B (es) Compuestos de piridina y pirazina sustituidos como inhibidores de pde4.
CR20200445A (es) Inhibidores de la arginasa
MX2024001394A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
MX2023004221A (es) Inhibidores de rad51.
MX2019003125A (es) Lamina de acero.
WO2014191521A3 (en) New compact scaffold of cas9 in the type ii crispr system
MX2013010653A (es) Polimeros que contienen azufre difuncionales modificados terminales, sus composiciones y metodos de uso.
TW200621766A (en) Substituted hydantoins
TW200621764A (en) Substituted hydantoins
AU2016335612B2 (en) Dental composition
MX2021004732A (es) Anticuerpos de cadena pesada que se unen a cd38.
MY162487A (en) Electrolytic copper foil, cleaning fluid composition and method for cleaning copper foil
WO2016051423A3 (en) An improved process for the preparation of enzalutamide
CL2019002322A1 (es) Uso de copolímeros como aglutinantes para la peletización de minerales que contienen metal.
MX2018001397A (es) Polimeros de poli acido carboxilico parcialmente descarboxilados.
MX2019007803A (es) Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
TN2015000318A1 (en) Oxidatively curable coating composition
EP3162770A3 (en) A method for efficiently recycling a stream containing iron sludge
EA201370163A1 (ru) Способы и композиции для лечения почечных нарушений
WO2011095812A3 (en) Composition comprising mixed metal compounds and xanthan
PE20180641A1 (es) Uso de copolimeros de asociacion hidrofoba como aglutinantes para granular minerales que contienen metales
MX2020008984A (es) Compuestos de ciclohexilo sustituido como inhibidores de nop.
MX2022003384A (es) Polimeros que contienen acido fenil boronico sustituido y metodos de uso.